天坛生物
(600161)
| 流通市值：253.30亿 | | | 总市值：253.30亿 |
| 流通股本：19.77亿 | | | 总股本：19.77亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,852,097,635.83 | 2,595,368,216.39 | 1,141,703,634.53 | 6,168,036,314.63 |
| 营业收入 | 3,852,097,635.83 | 2,595,368,216.39 | 1,141,703,634.53 | 6,168,036,314.63 |
| 二、营业总成本 | 3,115,605,323.5 | 2,083,907,451.48 | 949,243,685.91 | 4,315,509,249.08 |
| 营业成本 | 2,491,465,969.61 | 1,661,218,056 | 746,775,616.89 | 3,463,231,712.76 |
| 税金及附加 | 76,179,464.56 | 53,646,027.82 | 23,503,986.18 | 73,398,596.62 |
| 销售费用 | 89,884,624.2 | 52,515,185.84 | 21,747,340.81 | 124,903,052.79 |
| 管理费用 | 371,340,702.64 | 243,958,233.45 | 117,660,990.19 | 496,043,575.85 |
| 研发费用 | 85,802,112.69 | 71,918,610.55 | 39,185,592.87 | 159,993,236.22 |
| 财务费用 | 932,449.8 | 651,337.82 | 370,158.97 | -2,060,925.16 |
| 其中:利息费用 | 5,486,473.51 | 3,707,352.78 | 1,837,733.22 | 7,336,021.88 |
| 其中:利息收入 | 6,806,336.84 | 4,533,278.49 | 2,156,364.78 | 12,085,262.91 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 10,302,834.3 | 7,858,246.02 | 5,520,832.58 | 26,979,259.67 |
| 资产处置收益 | 21,397.95 | 21,397.95 | 21,397.95 | 104,452.59 |
| 资产减值损失(新) | -18,596,146.78 | -16,627,481.96 | -1,924,977.01 | -19,110,612.28 |
| 信用减值损失(新) | -2,391,572.59 | -5,684,810.93 | 5,300,409.86 | -65,197,479.13 |
| 其他收益 | 28,969,286.71 | 25,082,811.4 | 22,011,078.74 | 42,005,309.19 |
| 四、营业利润 | 754,798,111.92 | 522,110,927.39 | 223,388,690.74 | 1,837,307,995.59 |
| 加:营业外收入 | 381,284.85 | 184,979.22 | 109,229.93 | 2,763,350.32 |
| 减:营业外支出 | 4,643,395.99 | 1,445,238.33 | 280,480.93 | 17,347,553.51 |
| 五、利润总额 | 750,536,000.78 | 520,850,668.28 | 223,217,439.74 | 1,822,723,792.4 |
| 减:所得税费用 | 156,670,085.63 | 106,286,788.36 | 44,124,181.08 | 332,841,612.7 |
| 六、净利润 | 593,865,915.15 | 414,563,879.92 | 179,093,258.66 | 1,489,882,179.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 593,865,915.15 | 414,563,879.92 | 179,093,258.66 | 1,489,882,179.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 427,985,328.95 | 298,910,184.66 | 125,866,043.47 | 1,090,837,981.2 |
| 少数股东损益 | 165,880,586.2 | 115,653,695.26 | 53,227,215.19 | 399,044,198.5 |
| 扣除非经常损益后的净利润 | 415,352,356.39 | 284,814,193.44 | 113,354,599.51 | 1,076,327,393.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.22 | 0.15 | 0.06 | 0.55 |
| (二)稀释每股收益 | 0.22 | 0.15 | 0.06 | 0.55 |
| 八、其他综合收益 | 4,797,562.76 | 4,797,562.76 | 1,620,701.85 | - |
| 归属于母公司股东的其他综合收益 | 4,797,562.76 | 4,797,562.76 | 1,620,701.85 | - |
| 九、综合收益总额 | 598,663,477.91 | 419,361,442.68 | 180,713,960.51 | 1,489,882,179.7 |
| 归属于母公司股东的综合收益总额 | 432,782,891.71 | 303,707,747.42 | 127,486,745.32 | 1,090,837,981.2 |
| 归属于少数股东的综合收益总额 | 165,880,586.2 | 115,653,695.26 | 53,227,215.19 | 399,044,198.5 |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-30 | 2026-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |